Articles

Based on current drug pricing strategies in the United States, ribociclib combination therapy is unlikely to be cost-effective for treating postmenopausal patients with HR-positive HER2-negative advanced breast cancer. Read More ›

Read More ›

For patients with recurrent metastatic HER2-positive breast cancer, new therapies such as margetuximab will expand treatment options. Read More ›

To help inform treatment decision-making, guidelines have been developed on surveillance mammography for early breast cancer survivors who are ≥75 years of age. Read More ›

Patients reported satisfaction with nurse-led telephone end-of-treatment follow-up experiences; therefore, permanent modifications may be warranted. Read More ›

Breast cancer survival disparities persist even after adjusting for sociodemographic factors, tumor characteristics, and NCCN guideline–appropriate treatment, suggesting that social and environmental factors can impact survival. Read More ›

Interfacility variation in efforts to eliminate the use of unnecessary breast cancer procedures highlights the need for more formalized deimplementation plans. Read More ›